Global Locator
Genzyme Websites
Health Care Professionals
Company
Products
Research
Patients
Responsibility
Careers
News
About Genzyme
Company Leadership
Business Units
News
Press Contacts
Subscribe to News
Recognition and Awards
Working With Genzyme
Global Reach
Download Genzyme Materials
Today is September 20, 2024. All times in Eastern Daylight Time.
Genzyme Convenes 5th Annual Gaucher Leadership Forum in Madrid
11/21/2013 - 08:00 AM
Genzyme to Invest $80 Million in Framingham, Mass. Site to Expand Manufacturing Capacity for Fabrazyme®
10/15/2013 - 08:00 AM
Aubagio® Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study
10/03/2013 - 04:45 AM
Genzyme Announces Winners of Patient Advocacy Leadership (PAL) Awards
09/30/2013 - 08:00 AM
Genzyme’s Multiple Sclerosis Franchise Featured at ECTRIMS
09/26/2013 - 07:00 AM
Sanofi Forms Partnership with UMass Boston with $1 Million Support of Student Success Program for STEM Education
09/19/2013 - 07:30 AM
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)
09/17/2013 - 01:05 AM
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
08/30/2013 - 11:33 AM
Genzyme Convenes 1st International Gaucher Conference on Bone Disease
07/01/2013 - 08:00 AM
Genzyme Receives Positive CHMP Opinion for LEMTRADA™ (alemtuzumab) in Europe
06/28/2013 - 08:00 AM
Genzyme Convenes 14th Annual North American Lysosomal Storage Disorder Registries Meeting
06/12/2013 - 08:00 AM
Genzyme Celebrates Fifth Annual World MS Day
05/29/2013 - 09:00 AM
Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study
04/25/2013 - 01:00 AM
Genzyme Convenes 13th European Fabry Disease Roundtable
04/18/2013 - 08:00 AM
AUBAGIO® (teriflunomida) oral para administração uma vez por dia aprovado na Argentina para o tratamento de esclerose múltipla reincidente
04/08/2013 - 03:53 PM
AUBAGIO® (teriflunomida) una vez al día por vía oral, de Genzyme, autorizado en Argentina para el tratamiento de la esclerosis múltiple recurrente
04/08/2013 - 12:45 PM
Genzyme’s Once-daily, Oral AUBAGIO® (teriflunomide) Approved in Argentina for the Treatment of Relapsing Multiple Sclerosis
04/08/2013 - 09:00 AM
Genzyme Receives Positive CHMP Opinion in the European Union for Once-daily, Oral AUBAGIO® to Treat Relapsing-Remitting Multiple Sclerosis
03/22/2013 - 08:30 AM
Effect of Genzyme’s LEMTRADA™ Maintained in Patients Beyond Two-Year Pivotal MS Studies
03/21/2013 - 03:00 PM
Genzyme’s Multiple Sclerosis Franchise Featured at AAN
03/13/2013 - 02:00 AM
Genzyme’s Head of Rare Diseases Honored by the Genetic Disease Foundation
03/04/2013 - 08:30 AM
Genzyme Recognizes International Rare Disease Day with Global Awareness Programs and Launch of Third Annual Patient Advocacy Leadership (PAL) Awards
02/28/2013 - 01:30 AM
Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS)
02/27/2013 - 05:30 AM
Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease
02/15/2013 - 11:15 AM
Genzyme and Isis Announce FDA Approval of KYNAMRO™ (mipomersen sodium) Injection for the Treatment of Homozygous Familial Hypercholesterolemia
01/29/2013 - 06:30 PM
1
2
3
4
5
6
7
8
9
10
11
« Previous
Next »
infoBox
LinkedIn
Yahoo! Buzz
Facebook
Twitter
Delicious
DIGG